In vivo, BSTJF mirrored the RAGE inhibitor FPS-ZM1’s efficacy by ameliorating PCOS phenotypes through reducing GC apoptosis, attenuating AGEs accumulation, inflammatory cytokines and state of oxidative stress, normalizing carbohydrate metabolism and lipid homeostasis, and inhibiting AGEs-RAGE-NOX4 axis activation and NF-κB nuclear translocation in ovarian GCs. The gene discussed is NOX4; the disease is polycystic ovary syndrome.